EP0253490A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Controlled release combination of carbidopa/levodopa
Assignee: Merck and Co Inc
•
Filing: 1987-06-09
•
Granted: —
•
Expires: 2007-06-09
Abstract
Abstract A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
Inventors
- 👤 Robert E. Dempski
- 👤 Donald W. Nibbelink
- 👤 Edward C. Scholtz
- 👤 Scott A. Reines
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 21:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K9/205; A61K9/2054; A61P; A61P25/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
83 words
A process for preparing a controlled release oral dosage formulation which comprises forming a uniform dispersion of 5-300 mg of carbidopa, 2-1200 mg of levodopa, 0-25 mg of a tablet lubricant and optionally a pharmaceutically acceptable dye, in a polymer vehicle comprising 0-120 mg of a water soluble polymer and 0-120 mg of a less water soluble polymer, with the proviso that both polymers are not 0 mg, whereby following administration the carbidopa and levodopa are released slowly and simultaneously from the formulation.
Claim 2
Dependent Claim
83 words
A process for preparing a controlled release oral dosage formulation which comprises forming a uniform dispersion of 5-300 mg of carbidopa, 2-1200 mg of levodopa, 0-25 mg of a tablet lubricant and optionally a pharmaceutically acceptable dye, in a polymer vehicle comprising 0-120 mg of a water soluble polymer and 0-120 mg of a less water soluble polymer, with the proviso that both polymers are not 0 mg, whereby following administration the carbidopa and levodopa are released slowly and simultaneously from the formulation.
Claim 3
Dependent Claim
71 words
The process of Claim 1 wherein the polymer vehicle is: A water soluble polymer selected from hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, polyethylene glycol, starch and methyl cellulose; or a less water-soluble polymer selected from polyvinyl acetate-crotonic acid copolymer, polyvinyl chloride, polyethylene, cellulose acetate, polyvinyl alcohol, ethylene vinyl acetate copolymer, polyvinyl acetate, polymethyl methacrylate, and ethyl cellulose; or a combination of a water soluble polymer and a less water soluble polymer.
Claim 4
Dependent Claim
23 words
The process of Claim 2, wherein the polymer vehicle is a combination of a water soluble polymer and a less water soluble polymer.
Claim 5
Dependent Claim
24 words
The process of Claim 3, wherein the water soluble polymer is hydroxypropyl cellulose and the less water soluble polymer is polyvinyl acetate-crotonic acid copolymer.
Claim 6
Dependent Claim
68 words
The process of Claim l which comprises forming a uniform dispersion of 25-100 mg of carbidopa, 100-400 mg of levodopa, 1-10 mg of a tablet lubricant and optionally a pharmaceutically acceptable dye, in a polymer vehicle comprising 5-25 mg of a water soluble polymer and 2-50 mg of a less water soluble polymer, whereby following administration the carbidopa and levodopa are released slowly and simultaneously from the formulation.
Claim 7
Dependent Claim
71 words
The process of Claim 5 wherein the polymer vehicle is: A water soluble polymer selected from hydroxypropyl cellulose, hydroxypropylmethyl cellulose polyvinyl pyrrolidone, polyethylene glycol, starch and methyl cellulose; or a less water-soluble polymer selected from polyvinyl acetate-crotonic acid copolymer, polyvinyl chloride, polyethylene, cellulose acetate, polyvinyl alcohol, ethylene vinyl acetate copolymer, polyvinyl acetate, polymethyl methacrylate, and ethyl cellulose; or a combination of a water soluble polymer and a less water soluble polymer.
Claim 8
Dependent Claim
23 words
The process of Claim 6, wherein the polymer vehicle is a combination of a water soluble polymer and a less water soluble polymer.
Claim 9
Dependent Claim
24 words
The process of Claim 7, wherein the water soluble polymer is hydroxypropyl cellulose and the less water soluble polymer is polyvinyl acetate-crotonic acid copolymer.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.